^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)

Published date:
05/27/2020
Excerpt:
Among patients experiencing PD, the median plasma levels of stromal derived factor-1 and vascular endothelial growth factor-A were significantly higher compared with the baseline (P=0.01; P=0.011). Changes in levels of selected CAFs were associated with response/resistance to pazopanib in mRCC patients.
DOI:
10.1097/COC.0000000000000719
Trial ID: